Karen K. Ballen
A5045583767- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Chronic Myeloid Leukemia Treatments
- Mesenchymal stem cell research
- Immune Cell Function and Interaction
- Transplantation: Methods and Outcomes
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Childhood Cancer Survivors' Quality of Life
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Cancer survivorship and care
- Hematological disorders and diagnostics
- Palliative Care and End-of-Life Issues
- Histone Deacetylase Inhibitors Research
- Neonatal Respiratory Health Research
- Eosinophilic Disorders and Syndromes
- Virus-based gene therapy research
University of Virginia
2017-2025
University of Virginia Health System
2014-2024
University of Virginia Medical Center
2019-2024
University of Virginia Cancer Center
2017-2022
Wake Forest University
2018-2020
Forest Institute
2018-2020
Charlottesville Medical Research
2018-2020
John Wiley & Sons (United States)
2017-2020
Massachusetts General Hospital
2010-2019
Health Center
2019
Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant (HSCT) community. In present report we propose to define regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity (RIC), and (3) nonmyeloablative (NMA) conditioning. Assignment these categories is based on duration of cytopenia requirement (SC) support: MA cause irreversible SC support mandatory. NMA minimal cytopenia, can be given also without support. RIC...
During the 2006 BMT Tandem Meetings, a workshop was convened by Center for International Blood and Marrow Transplant Research (CIBMTR) to discuss conditioning regimen intensity define boundaries of reduced-intensity (RIC) before hematopoietic cell transplantation (HCT). The goal determine acceptance available RIC definitions in transplant community. Participants were surveyed regarding their opinions on specific statements intensity. Questions covered "Champlin criteria," as well operational...
Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions cyclophosphamide in patients scleroderma.
Umbilical cord blood (UBC) stem cells are a useful cell source for patients without matched related or unrelated donors. Adult transplantation with single UBC units is associated high transplantation-related mortality (TRM). In most cases, due to infection slow engraftment and immunoincompetence. this study, we used reduced-intensity conditioning regimen of fludarabine, melphalan, antithymocyte globulin followed by 2 partially units. The were 4/6 HLA match better each other the patient...
On the basis of data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on pediatric protocols, we assessed feasibility treating aged 18–50 years ALL DFCI Pediatric Consortium regimen utilizing a 30-week course pharmacokinetically dose-adjusted E. coli L-asparaginase during consolidation. Between 2002 2008, 92 eligible were enrolled at 13 participating centers. Seventy-eight (85%) achieved complete remission (CR)...
Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification patients and development newer treatment options. Identification ALL subtypes based on immunophenotyping cytogenetic molecular markers has resulted in inclusion Philadelphia-like early T-cell precursor that affect prognosis. Ikaros mutations also emerged a prognostic factor. In addition prognostication, options for with have expanded, particularly regard relapsed/refractory...
BACKGROUND We conducted a study to investigate the impact of hospitalization for hematopoietic stem cell transplantation (HCT) on quality life (QOL) and mood patients family caregivers (FC). METHODS longitudinal who were hospitalized HCT their FC. assessed QOL (using Functional Assessment Cancer Therapy‐Bone Marrow Transplantation) Hospital Anxiety Depression Scale) at baseline (6 days before HCT), day +1, +8 HCT. administered Medical Outcomes Study Health Survey Short Form‐36 examine FC...
Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving for primary myelofibrosis between 1989 and 2002, from database Center International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings...
Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT).We assessed changes in incidence TRM and overall survival from 1985 through 2004 5,972 patients younger than age 50 years who received myeloablative conditioning HCT for acute myeloid leukemia (AML) first complete remission (CR1) or second (CR2).Among HLA-matched sibling donor recipients, relative risks (RRs) were 0.5 0.3 2000 compared with those 1989 CR1 CR2,...
Double umbilical cord blood (DUCB) transplantation is an accepted strategy for patients without suitable human leukocyte antigen (HLA) matched donors. However, DUCB associated with increased morbidity and mortality because of slow recovery immunity a high risk infection. To define the differences in immune reconstitution between HLA unrelated donor (MUD) transplantation, we performed detailed, prospective analysis 42 recipients 102 filgrastim-mobilized peripheral stem cell recipients....
We performed a retrospective study analysing the effect of sorafenib, an oral fms-Like Tyrosine Kinase 3 (FLT3)/multikinase inhibitor, as post-transplant maintenance in adult patients with FLT3-internal tandem duplication (ITD) acute myeloid leukaemia (AML). identified consecutive FLT3-ITD AML diagnosed between 2008 and 2014 who received haematopoietic cell transplantation (HCT) first complete remission (CR1). Post-HCT initiation sorafenib (yes/no) was evaluated time-varying covariate...
Specific tolerance after combined kidney and bone marrow transplantation for multiple myeloma with end-stage renal disease through mixed lymphohematopoietic chimerism has been achieved, as evidenced by prolonged normal function without ongoing immunosuppression.To achieve potent antimyeloma responses induce the allograft, seven patients (median age: 48 years [range: 34-55 years]) underwent a human leukocyte antigen-matched transplant lead follow-up time of more than 12 years. Preparative...